Influenza

Safety and Efficacy: IV Zanamivir vs Oral Oseltamivir in Severe Influenza

By

Cindy Lampner

Intravenous zanamivir is as safe and effective as oral oseltamivir when used in patients with severe influenza.

Reactogenicity of Enhanced Influenza Vaccines in Older Adults

By

Bradley van Paridon

A team of investigators report on the findings from a randomized controlled trial of 3 enhanced influenza vaccines and a standard-dose vaccine in older adults.

Prior Influenza Exposure and Age Could Affect Vaccine Efficacy

By

Brandon May

Age and prior exposure to the H1 or B influenza virus may affect the cross-reactivity of H3-specific postvaccination responses and influence the efficacy of the seasonal influenza vaccine.

FDA to Review Baloxavir for Pediatric Use, Postexposure Prophylaxis of Influenza

By

Diana Ernst, RPh

Baloxavir inhibits the endonuclease activity of the polymerase acidic protein resulting in inhibition of influenza virus replication.

Neuraminidase Inhibitor Treatment for Influenza B-Related Pneumonia

By

Zahra Masoud

Early neuraminidase inhibitor therapy may result in better outcomes in patients hospitalized with influenza B-related pneumonia.

Adjuvanted FLU-v Vaccine Immunogenic in Healthy Adults

Results of early research support further development of a synthetic universal influenza vaccine.

Evaluation of Trivalent vs Quadrivalent Inactivated Vaccine for Influenza B

By

Sweta Gupta

Despite the higher effectiveness of the quadrivalent inactivated influenza vaccine against the added B virus lineage, trivalent inactivated influenza vaccine.

Antibiotic and Antiviral Combination to Treat Influenza

By

Zahra Masoud

Compared with patients prescribed only an antiviral, patients who are prescribed both an antiviral and antibiotic have a lower risk for 3-day respiratory hospitalization.

Fluad Quadrivalent Influenza Vaccine Approved for Older Adults

By

Diana Ernst, RPh

The FDA has approved Fluad Quadrivalent (influenza vaccine, adjuvanted; Seqirus) for active immunization in patients 65 years of age and older against influenza disease caused by influenza virus subtypes A and types B contained in the vaccine.